Therapeutic Effects of Epidermal Growth Factor on Benzalkonium Chloride–Induced Dry Eye in a Mouse Model by Xinye Xiao et al.
Therapeutic Effects of Epidermal Growth Factor on
Benzalkonium Chloride–Induced Dry Eye in a
Mouse Model
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Yueping Zhou,1 and Zuguo Liu1,3
PURPOSE. To investigate the therapeutic effects and possible
mechanisms of epidermal growth factor (EGF) on the mouse
dry eye model induced by benzalkonium chloride (BAC).
METHODS. The eye drop containing EGF was topically admin-
istered (3 ng per day) on a BAC-induced dry eye model. The
following clinical indications of dry eye were evaluated on
Days 2, 4, and 6: tear break-up time (BUT), corneal fluorescein
staining, inflammatory index, and tear volume. Global speci-
mens were collected on Day 6 and then the following exami-
nations were performed: histologic investigation, TUNEL assay
to measure the dead cells, periodic acid-schiff (PAS) assay to
detect goblet cells, and immunostaining of antibodies of Ki-67,
EGF receptor (EGFR), and MUC1 in the corneas. The levels of
EGFR and p-ERK of the corneas were also measured by West-
ern blot analysis.
RESULTS. EGF resulted in longer BUTs on Days 2 and 6, lower
fluorescein staining scores on Days 4 and 6, while no signifi-
cant changes in inflammatory index or tear volume. EGF in-
duced higher EGFR expression in corneal tissues by immuno-
fluorescent staining and Western blot analysis. EGF also
upregulated p-ERK, increased Ki-67 positive cells, and de-
creased TUNEL positive cells. In addition, EGF significantly
increased the goblet cells number and MUC1 expression in the
epithelium.
CONCLUSIONS. Topical application of EGF presented clinical
improvements on dry eye by stabilizing the tear film and
maintaining the integrity of epithelium. The results indicate
that EGF has potential as a therapeutic agent in clinical treat-
ment of dry eye. (Invest Ophthalmol Vis Sci. 2012;53:191–197)
DOI:10.1167/iovs.11-8553
Dry eye is a multifactorial disease of the tears and ocularsurface that results in symptoms of discomfort, visual
disturbance, and tear film instability with potential damage to
the ocular surface. It is accompanied by increased osmolarity
of the tear film and inflammation of the ocular surface.1 As one
of the most common ocular diseases, dry eye affects 15% to
35% of the population worldwide.2–4 Patients often complain
about dryness, redness, burning, and sandy-gritty eye irritation.
If the condition is left untreated or aggravates, it may produce
complications including corneal epithelium damage, squamous
metaplasia, and neovascularization.
Among numerous managements for dry eye, the first-line
choice is topical application of artificial tears which has been
proven to relieve symptoms of irritation and decrease corneal
dye staining in mild to moderate clinical conditions. However,
the imperfect performance of artificial tears in severe cases
may result from lack of active agents such as epidermal growth
factor (EGF), hepatocyte growth factor, fibronectin, neu-
rotrophic growth factor, and vitamin A. These essential com-
ponents in the tear film play important roles in maintaining
ocular surface health. Topical application of autologous serum
(AS), which can supplement the active agents, leads to recov-
ery in many severe dry eye cases.5–7 However, the relatively
complicated preparation and safety concerns limit its use in
individuals.
EGF is the key component of both tear film and serum. EGF
is a potent polypeptide mitogen that belongs to the EGF family
of growth factors. It has been demonstrated that EGF in the
tear film is secreted by the lacrimal gland and plays a vital role
in the corneal epithelium maintenance and wound healing.8–11
Symptoms of dry eye in patients with solid tumors treated with
systemic therapy of EGF receptor (EGFR) inhibitor, led to the
hypothesis that topical application of EGF may be a promising
therapy for dry eye.12 However, the efficacy of EGF eye drops
on dry eye has not been adequately discussed so far. The aim
of this study was to investigate the therapeutic effects of EGF
on the mouse dry eye models induced by topical administra-
tion of benzalkonium chloride (BAC)13,14 and the mechanisms
underlying these effects.
METHODS AND MATERIALS
Mouse Dry Eye Model
Twenty-eight male BALB/c mice (18 to 20 g, purchased from Shanghai
SLAC laboratory animal center, Shanghai, China) were used for this
study. These mice were kept in the facility with standard environment
throughout the study as follows: room temperature 25  1°C, relative
humidity 60%  10%, and alternating 12-hour light-dark cycles (8 AM
to 8 PM). All experimental procedures were performed in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and the experimental protocol was approved by the
experimental animal ethics committee of Xiamen University. Both eyes
of 21 mice were topically administered twice daily (9 AM, 9 PM), 5 L
of 0.2% BAC for 14 days.13,14 Based on the clinical evaluations (de-
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scribed below), the mice with dry eye condition were then randomly
divided into three groups: blank control group, solvent-treated group,
and EGF-treated group. The other 7 mice were raised for normal
control.
Experimental Procedure
After grouping, the blank control group was left untreated for baseline
comparison. The solvent-treated group was administered with solvent
of EGF (primarily glycerol; Watsin Genetech, Shenzhen, China) and the
EGF-treated group with EGF solution (200 ng/mL; Watsin Genetech)
with the dosage of 5 L, three times per day (8 AM, 3 PM, 10 PM).
During the treatment (on Day 2, 4, and 6), the clinical evaluations were
performed by a single masked ophthalmologist. On Day 6, all mice
were euthanized and the ocular or orbit tissues were carefully dis-
sected and harvested for histologic and Western blot analysis following
the methods described below.
Break-Up Time (BUT) and Fluorescein Staining
One microliter of 0.1% liquid sodium fluorescein was dropped into the
conjunctival sac. After 3 blinks, BUT was recorded in seconds. Ninety
seconds later, corneal epithelial damage was graded with a cobalt blue
filter under a slit-lamp microscope (Kanghua Science & Technology,
Chongqing, China). The cornea was divided into four quadrants, which
were scored respectively. The four scores were added to a final grade
(total, 16 points). The fluorescein score was analyzed as previously
described15 with essential modification; it was briefly as follows: ab-
sent, 0; slightly punctuate staining 30 spots, 1; punctate staining 30
spots, but not diffuse, 2; severe diffuse staining but no positive plaque,
3; and positive fluorescein plaque, 4.
Evaluation of Inflammation
The inflammatory index was analyzed as previously described.16
Briefly, the inflammatory index was evaluated, based on three param-
eters: ciliary hyperemia (absent, 0; present but 1 mm, 1; present
between 1 and 2 mm, 2; present 2 mm, 3); central corneal edema
(absent, 0; present with visible iris details, 1; present without visible
iris details, 2; present without visible pupil, 3); and peripheral corneal
edema (absent, 0; present with visible iris details, 1; present without
visible iris details, 2; present with no visible iris, 3). The final inflam-
matory index result was obtained by summing the scores of the
different parameters then dividing by a factor of nine.
Measurement of Tear Volume
Tear production was measured by the phenol red thread tear test using
cotton threads (Zone-Quick; Yokota, Tokyo, Japan)17 at a similar time
point (7 PM) on Days 0, 2, 4, and 6 in the standard environment. Mice
were kept immobile by intraperitoneal injection of 60 mg/kg pento-
barbital. The lower eyelid was pulled down slightly, and a 1 mm
portion of the thread was placed on the palpebral conjunctiva for 15
seconds at a specified point approximately one third of the distance
from the lateral canthus of the lower eyelid. The red portion of the
thread is measured in millimeters.
Immunofluorescent and
Immunohistochemical Staining
Both immunofluorescent and immunohistochemical staining were per-
formed on cryosections (6 m thick) of the eyeballs. Sections for
immunofluorescent staining were fixed in acetone at 20°C, blocked,
and incubated at 4°C overnight with the EGFR antibody (1:50,000;
Abcam, San Francisco, CA) and the MUC1 antibody (1:100; Abcam).
After incubation in AlexaFluor 488-conjugated IgG (1:1000; Invitrogen,
Carlsbad, CA), sections were counterstained with DAPI (Vector, Bur-
lingame, CA), mounted, and photographed using the confocal laser
scanning microscope (Fluoview FV1000; Olympus, Tokyo, Japan). Cor-
neas were scanned in the same area in each group. For immunohisto-
chemical staining, the endogenous peroxides activity was quenched
with 0.6% hydrogen peroxide in PBS for 30 minutes. After incubating
with 2% BSA, the antibodies of Ki-67 (1:400; Abcam) was applied and
incubated at 4°C for 14 to 18 hours. After rinsing with PBS, the sections
were further incubated with biotinylated anti-rabbit IgG (1:50) using
kits (Vectastain Elite ABC; Vector Laboratories, Inc., Burlingame, CA)
according to the manufacturer’s protocol. The reaction product was
then developed with diaminobenzidine (DAB), the peroxidase sub-
strate for 60 seconds and mounted with mounting medium (H-5000;
Vector) and examined under a light microscope (Nikon Eclipse 50i;
Tokyo, Japan). The counterstaining with hematoxylin was not per-
formed to avoid interference from the nuclear staining.
Western Blot Analysis
Proteins of corneas from each group were extracted with cold RIPA
buffer. Equal amounts of proteins of the cell lysates were subjected to
electrophoresis on 8% or 11% SDS-PAGE and then electrophorectially
transferred to PVDF membranes. After 1-hour blocking in 2% BSA, the
membranes were incubated with primary antibodies for EGFR (1:
50,000; Abcam), Phospho-p44/42 ERK and p44/42 ERK (1:1000; Cell
Signaling Technology, Inc., Danvers, MA) and -actin (1:10,000; Sigma,
St. Louis, MO) as a loading control. After three washes with Tris-
buffered saline with 0.05% Tween-20 for 10 minutes each, the mem-
branes were incubated with HRP-conjugated goat anti-rabbit IgG (1:
10,000; Bio-Rad, Hercules, CA) for 1 hour. The specific bands were
visualized by enhanced chemiluminescence reagents (Lulong Inc., Xia-
men, China) and recorded by the transilluminator (ChemiDoc XRS;
Bio-Rad).
In Situ Terminal Deoxynucleotidyl Transferase
dUTP Nick End Labeling (TUNEL)
To measure end-stage apoptosis, in situ TUNEL was performed in frozen
sections using an assay (DeadEnd Fluorometric TUNEL System G3250;
Promega, Madison, WI) according to manufacturer’s instructions. Sections
were counterstained with DAPI (Vector), mounted, and the photo images
were taken with a confocal laser scanning microscope (Fluoview FV1000;
Olympus). For the positive control, sections were incubated in DNase I
before the addition of equilibration buffer, while DDW was used instead
of TdT reaction mix in the negative control.
Periodic Acid-Schiff (PAS) Staining
The goblet cells in conjunctival fornices were stained by a PAS staining
system (PAS Staining System 395B-1KT; Sigma) in the paraffin sections
of the whole orbit tissue. Goblet cells were counted in six represen-
tative slices of homologous positions of tissues from each group. The
average numbers of goblet cells were included for comparison. The
counterstaining with hematoxylin was performed.
Statistical Analysis
Two-way ANOVA (Bonferroni posttest) was applied to make compar-
isons between groups at different time points. Differences with P
values  0.05 were considered statistically significant.
RESULTS
EGF Ameliorated the Stability of Tear Film and
Epithelium Damage
To determine whether EGF has beneficial effects on the dry
eye, we used the BAC-induced experimental setting that we
established and reported recently.14 Briefly, BAC was topically
administered at a dosage of 0.2 g daily for 14 days. The
clinical evaluations of BUT, corneal fluorescein staining, inflam-
matory index, and tear volume were identical in three groups:
the blank control group, the solvent-treated group, and the
EGF-treated group (D0; Fig. 1).
It was demonstrated that there was a general trend of
extending BUT (Fig. 1A) and decreasing fluorescein staining
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scores (Fig. 1B) of each group after the BAC administration
stopped. However, it was shown that EGF at the dose of 3 ng
daily statistically significantly increased BUT on Day 2 and Day
6 while decreased fluorescein staining scores on Days 4 and 6,
compared with both the blank control group and the solvent-
treated. Meanwhile, we also measured inflammatory index and
tear volume changes after EGF treatment. It was shown that
inflammatory indexes decreased since the termination of BAC
administration while phenol red thread tear volume tests kept
at the same level to the baseline of this study (Figs. 1C, 1D).
EGF did not induce significant changes of inflammatory index
and tear volume among 3 groups at all time points during the
treatment (Figs. 1C, 1D). In addition, it was revealed by the
H&E staining that EGF-treated corneas had smoother epithe-
lium compared with the blank control group and solvent-
treated group (Fig. 2).
Alteration of Epidermal Growth Factor Receptor
To elucidate the mechanism underlying the above effects of
EGF on the dry eye, we focused on the key factor of the EGF
pathway: EGFR with immunofluorescent staining and Western
blot assay. It was demonstrated that BAC induction reduced
the volume of corneal EGFR in the blank control group and
the solvent-treated group, compared with normal control
(Figs. 3A–F ), meanwhile, interestingly the treatment of EGF
resulted in a high density of EGFR expression in the corneal
epithelium (Figs. 3G, 3H). In addition, the Western blot anal-
ysis results also showed EGFR level of the cornea was lower in
the blank control group and the solvent-treated group than that
of normal ones. EGF administration induced a high level of
EGFR (Fig. 3I), which was consistent with the results of immu-
nofluorescent staining images.
Effects of EGF on Phosphorylation of ERK, Cell
Proliferation, and Apoptosis
To further investigate the mechanism of EGF’s effects on dry
eye, we conducted studies by examining the changes of down-
stream pathway of EGF (i.e., the phosphorylation of ERK, the
alterations of cell proliferation and apoptosis).
FIGURE 1. Alterations of ocular sur-
face clinical evaluations on Days 0, 2,
4, and 6 in each group. The blank
control group was left untreated, the
solvent-treated group and the EGF-
treated group was administered with
solvent of EGF (primarily glycerol)
and EGF (3 ng per day) respectively.
(A) Tear film break-up time. (B) Flu-
orescein staining. (C) Inflammatory
index. (D) Tear volume. Data are pre-
sented as the mean  SD, n  14.
**P  0.01, ***P  0.001, EGF versus
control; P  0.05, P  0.01,
P  0.001, EGF versus solvent.
The normal values of BUT, fluores-
cein staining, inflammatory index,
and tear volume were 7.2 seconds, 0,
0, and 6.3 mm respectively.
FIGURE 2. Representative images of
corneal epithelium integrity includ-
ing fluorescein staining with a cobalt
blue filter under a slit-lamp micro-
scope on Day 6 (A–D) and H&E stain-
ing (E–H, magnification, 200). (A, E)
The normal control. (B, F) The blank
control group. (C, G) The solvent-
treated group. (D, H) The EGF-treated
group. The smoother epithelium was
observed by H&E staining, compared
with the blank control group and the
solvent-treated group.
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It was shown by Western blot analysis that p-ERK level was
low in the BAC-induced dry eye models, while treatment of
EGF upregulated p-ERK level (Fig. 4A), indicating that the
effects of EGF is mediated with the p-ERK.
We detected the level of Ki-67 to determine the growth
fraction of epithelium, because Ki-67 is known to be present
during active phases of the cell cycle (G1, S, G2, and mitosis)
but absent from resting cells (G0).18 It was demonstrated with
immunohistochemical staining that the number of Ki-67 posi-
tive cells was low in normal conditions (Fig. 4B1). Few cells
were labeled by Ki-67 in both the blank control group and
solvent-treated group (Figs. 4B2, 4B3). Meanwhile EGF treat-
ment induced more Ki-67 positive cells (Fig. 4B4). Our data
suggested that EGF increased the cell proliferation in the dry
eye condition.
We also examined changes of the cell death by the TUNEL
assay. It was revealed that dry eye condition resulted in more
cell death in corneal epithelium in both the blank control
group and the solvent-treated group compared with the nor-
mal control group, meanwhile EGF treatment alleviated the
cell death in corneal epithelium (Fig. 4C).
Effects of EGF on Density of Goblet Cells
and Mucins
To determine whether EGF has effects on the mucins of tear
film, we studied the MUC5AC which is secreted by goblet cells,
and the MUC1 which is tethered to the epithelial membrane.
We investigated MUC5AC by counting the number of goblet
cells with PAS staining (Fig. 5E). It was demonstrated that PAS
positive cells in the conjunctiva was decreased in the dry eye
model (Figs. 5A–C), while EGF treatment significantly in-
creased the number of goblet cells (Fig. 5D).
As one of membrane tethered mucins on the ocular surface,
MUC1 was studied with immunofluorescent staining. It was
revealed that MUC1 was expressed in the whole corneal epi-
thelium (Figs. 6A, 6B) while the expression was weak in the
dry eye condition (Figs. 6C, 6D). Meanwhile EGF treatment
increased the level of MUC1, compared with that of solvent-
treated group (Figs. 6E–H).
DISCUSSION
Dry eye is a common ocular surface disease initiated by various
stresses. Numerous animal models19,20 have been developed to
imitate certain pathophysiologic mechanisms to evaluate vari-
ous promising therapies. The BAC-induced model was intro-
duced in this study because its pathogenesis is identical with
some initial stresses of dry eye, such as administration of eye
drops with preservative in the chronic disease, toxic gas
from worsened environment dissolved in the tear film, and
the mild chemical burn. Furthermore, BAC-induced dry eye
model shared the same pathologic changes with human dry
eye, for example, epithelial apoptosis, goblet cell loss, tear
film defect and the inflammation, which were revealed in
the previous reports.14,21 Epidermal growth factor has been
widely used in managing many ocular surface diseases, such
as trauma and infection,8 –11 however the efficacy of EGF eye
drop on the dry eye has not been adequately discussed. Our
study demonstrated the therapeutic effects of EGF to treat
dry eye in vivo. The mechanisms underlying these effects
include epithelium maintenance by promoting epithelium
proliferation and inhibiting apoptosis, as well as tear film
supplement by increasing goblet cell number and maintain-
ing MUC1 expression. As the key component in the tear
film, EGF has great potential as an agent for the treatment of
dry eye.
The EGFR belongs to the receptor tyrosine kinase family
which is widely expressed in the ocular surface. The activation
of EGFR was involved in physiological procedures of cell pro-
liferation, migration, differentiation, and apoptosis through
multiple signal transduction pathways, particularly mitogen-
activated protein kinases (MAPKs).22,23 Administration of BAC
resulted in inflammation of the ocular surface,15,24 leading to
the decrease of EGFR on the epithelial cell membranes, which
may also occur in other types of dry eye. It was noticed that
topical application of EGF induced the expression of EGFR
(Fig. 3), which might be due to the signaling transduction and
its proliferative effect on renewing the epithelium. However,
specific mechanisms were not clear and it remains to be fur-
ther investigated and elucidated. Abundant EGFR on the cell
FIGURE 3. Representative images for corneal EGFR immunolabeling
(A, C, E, G), merged with DAPI (B, D, F, H), and Western blot of
corneal EGFR expression (I). EGFR was expressed on normal corneal
epithelium (A, B) especially in the basal layer. The expression of EGFR
decreased in dry eye condition (C, D). The solvent (E, F) did not show
significant effect on the EGFR expression while higher density of EGF
expression in EGF-treated group (G, H) was detected. The Western
blot result (I) was consistent with confocal images.
194 Xiao et al. IOVS, January 2012, Vol. 53, No. 1
membrane of the EGF-treated group were inclined to bind with
extra EGF, resulted in autophosphorylation of tyrosine resi-
dues, and prompted downstream activations. It was confirmed
by our in vivo study that the ERK1/2, also known as classical
MAPKs, was activated by EGF through autophosphorylation
(Fig. 4A), leading to DNA synthesis and cell proliferation25 (Fig.
4B) and antiapoptosis26 (Fig. 4C). Other functions of EGF, such
as modulation of cell migration, adhesion, and immune re-
sponse, might also be present.27,28
Goblet cells are highly specialized epithelial cells located
in the apical surface of the conjunctiva. The main functions
of goblet cells are synthesizing, storing, and secreting
MUC5AC for the mucous component of the tear film.
Chronic or severe inflammation in the dry eye condition can
reduce the goblet cells,29,30 which was confirmed in our
study (Fig. 5). We demonstrated that goblet cells increased
significantly after 6 days treatment of EGF, which was con-
sistent with the previous in vitro study31 in that EGF acti-
vated p44/p42 MAPK and promoted proliferation in human
and rat goblet cells. It is believed that goblet cell number is
associated with the secretion of MUC5AC,32,33 which con-
tribute to the lubrication and infection prevention of the
ocular surface. The improvement of BUT (Fig. 1) may also
result from more MUC5AC being secreted from goblet cells
in the EGF-treated group. The direct observation of MUC5AC
with immunolabeling was not performed because MUC5AC
is a secretory protein, and the pattern may not reflect its real
functional status. In addition to MUC5AC, several other
membrane-spanning mucins of corneal epithelium are im-
portant components of mucous layer of tear film, such as
FIGURE 4. ERK was phosphorylated
with the effect of promoting cell pro-
liferation and inhibiting apotosis. (A)
The phosphorylation of ERK was val-
ued by Western blot and the expres-
sion of p-ERK was upregulated in the
EGF-treated cornea. (B) Immunohisto-
chemical staining of Ki-67 was per-
formed to observe the growth fraction
of epithelium (magnification, 400).
More proliferative epithelial cells were
marked in EGF-treated group (B4),
compared with normal control (B1),
blank control group (B2) and solvent-
treated group (B3). (C) TUNEL assay
was applied to measure the cell death
of corneal epithelium. Few cells were
marked in normal control (C1, C2) and
EGF-treated cornea (C7, C8), while
massive dead cells were detected in
the blank control group (C3, C4) and
the solvent-treated group (C5, C6).
FIGURE 5. The alterations of goblet cells in conjunctiva observed by PAS staining (magnification, 400). (A) Normal conjunctival fornix. (B)
Conjunctival fornix of the blank control group. (C) Conjunctival fornix of the solvent-treated group. (D) Conjunctival fornix of the EGF-treated
group. (E) Mean PAS positive cell numbers of each group. **P  0.01, ***P  0.001.
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MUC1, MUC4, MUC16, and MUC19.34 We evaluated the
expression of MUC1 by immunolabeling (Fig. 6). It was
demonstrated that MUC1 was impaired in the BAC-induced
dry eye compared with the normal specimens, which was
consistent with a previous study of Sjögren’s syndrome.35
The effect of EGF on promoting epithelial (including goblet
cells) proliferation and supplementing the mucous layer
could maintain the MUC1 expression in dry eye condition,
which contributed to the tear film stability in return. And
then, the improvement of tear film offered better protection
of corneal epithelium. In summary, topical application of
EGF can benefit tear film in dry eye condition by supple-
menting the amount of MUC1, MUC5AC, and probably other
mucins.
Collectively, topical application of EGF showed clinical
improvements on BAC-induced mouse dry eye by stabilizing
the tear film, and maintaining the integrity of epithelium,
which were supported by histologic assessments. The effect
of EGF on promoting proliferation, preventing apoptosis on
ocular surface of dry eye condition was also confirmed in
vivo. Furthermore, it was revealed for the first time that EGF
could supplement tear film by increasing the number of
goblet cells and maintaining MUC1 expression. Our study
indicated that EGF had a great potential to be a therapeutic
agent in the clinical treatment of dry eye.
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